Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Dec;10(12):1062-6.
doi: 10.1111/j.1469-0691.2004.01009.x.

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

P-R Hsueh  1 , L-M Huang, P-J Chen, C-L Kao, P-C Yang
Affiliations

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

P-R Hsueh et al. Clin Microbiol Infect. 2004 Dec.

Abstract

Abstract Serum levels of IgG, IgM and IgA against severe acute respiratory distress syndrome (SARS)-associated coronavirus (SARS-CoV) were detected serially with the use of immunofluorescent antibody assays in 30 patients with SARS. Seroconversion for IgG (mean 10 days) occurred simultaneously, or 1 day earlier, than that for IgM and IgA (mean 11 days for both). IgG could be detected as early as 4 days after the onset of illness. The earliest time at which these three antibodies reached peak levels was similar (mean 15 days). A high IgG level (1:800) could persist for > 3 months. The kinetics of neutralisation antibodies obtained with 100x the tissue culture infective dose (TCID50) of the SARS-CoV TW1 strain in five patients with SARS nearly paralleled those for IgG. There were no significant differences in the kinetics of the IgG, IgM and IgA responses between patients with or without underlying medical disease, steroid or intravenous immunoglobulin therapy, or mechanical ventilation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chronological evolution of IgG, IgM, and IgA antibodies to SARS‐associated coronavirus (SARS‐CoV) in 30 patients with SARS. (a) Cumulative proportion against time required for seroconversion to IgG, IgM and IgA according to immunofluorescent antibody (IFA) assays. (b) Cumulative proportion against time required for seroconversion to IgG according to ELISA. (c) Cumulative proportion against time required for peak levels of antibodies according to IFA assays.
Figure 2
Figure 2
Dynamic changes of IgG, IgM, IgA and neutralisation (NT) antibodies against SARS‐CoV in two previously healthy patients with SARS. (a) Antibody changes in a SARS patient who received corticosteroid, intravenous immunoglobulin (IVIG) and mechanical ventilation. (b) Antibody changes in a SARS patient who received corticosteroid therapy only.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Severe Acute Respiratory Syndrome (SARS): summary table of SARS cases by country, 1 November 2002. http://www.who.int/csr/sars/country/table2003_09_23/en/ (accessed 26 September 2003).
    1. Hsueh PR, Hsiao CH, Yeh SH et al. Microbiologic characteristics, serologic response, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis 2003; 9: 1163–1167. - PMC - PubMed
    1. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966.DOI: 10.1056/NEJMoa030781 - DOI - PubMed
    1. Lee N, Hui D, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–1994.DOI: 10.1056/NEJMoa030685 - DOI - PubMed
    1. Poutanen SM, Low DE, Henry B et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348: 1995–2005.DOI: 10.1056/NEJMoa030634 - DOI - PubMed